Legend Biotech Corp
LEGNHealthcare|Biotechnology|USA
$27.08
-0.32 (-1.17%)
Tangible Book
$5.02
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
1435.27,
1826.89,
2119.55,
2420.3,
2780.63
],
"ebit_estimate": [
6.88,
258.15,
460.11,
586.33,
871.41
],
"ebitda_estimate": [
56.41,
290.7,
415.44,
353.8,
583.84
],
"net_income_estimate": [
13.03,
292.6,
493.07,
523.26,
829.11
],
"per_share_eps_estimate": [
0.1,
0.91,
1.14,
1.28,
2.56
],
"eps_nri_estimate": [
0.07,
0.79,
1.02,
1.37,
2.16
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
6.62,
7.86,
10.33,
8.18,
10.75
],
"pretax_income_estimate": [
22.55,
339.28,
565.28,
628.2,
1019.17
],
"operating_cash_flow_per_share_estimate": [
0.37,
1.57,
3.04,
2.25,
2.6
],
"roa_estimate": [
-0.7,
7.2,
13.5,
24.6,
22.3
],
"roe_estimate": [
3.36,
20.24,
24.71,
31.5,
27.2
],
"gross_margin_estimate": [
61.16,
66.85,
70.48,
74.67,
75.33
],
"operating_cash_flow_estimate": [
68.49,
290.61,
562.7,
416.48,
481.26
],
"pettm_estimate": [
273.54,
29.66,
23.67,
21.09,
10.58
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "27.24",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 27.24,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 52.01,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 5.71,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712",
"202803"
],
"revenue_estimate": [
362.81,
368.42,
395.1,
428.77,
456.83,
484.9,
521.33,
544.7
],
"ebit_estimate": [
24.15,
14.1,
20.88,
63.08,
78.26,
94.82,
117.73,
137.14
],
"ebitda_estimate": [
17.32,
35.21,
53.37,
80,
86,
85,
87,
134
],
"net_income_estimate": [
35.22,
22.81,
20.93,
58.84,
81.86,
107.07,
142.03,
12.59
],
"per_share_eps_estimate": [
0.11,
0.1,
0.16,
0.15,
0.21,
0.28,
0.36,
0.07
],
"eps_nri_estimate": [
0.09,
0.06,
0.09,
0.24,
0.29,
0.37,
0.4,
null
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
42.92,
22.4,
30.18,
60.94,
84.46,
110.17,
145.63,
32.04
],
"operating_cash_flow_per_share_estimate": [
0.23,
0.15,
0.26,
0.23,
0.15,
0.26,
0.37,
0.15
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
64.75,
64.2,
64.58,
67,
67.33,
67.67,
66,
72.5
],
"operating_cash_flow_estimate": [
42.57,
27.77,
48.13,
42.57,
27.77,
48.13,
68.49,
27.77
],
"pettm_estimate": [
52.28,
44.39,
34.5,
27.35,
29.76,
null,
null,
null
],
"long_term_growth_rate_mean": 0,
"long_term_revenue_growth_rate_mean": "27.24",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": null,
"future_revenue_estimate_growth": 27.24,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": 52.01,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": 5.71,
"future_operating_cash_flow_per_share_estimate_growth": null
}